Interim Analysis of Beta-blocker Use in Traumatic Brain Injury
Key Highlights
This interim analysis explores the impact of early administration of beta-blockers on adrenergic surge, pro-inflammatory cytokines, and traumatic brain injury (TBI) biomarkers.
Patients with positive high-sensitivity troponin T (HsTnT) levels received propranolol, while those with negative test were randomized to receive propranolol or placebo.
Propranolol administration showed a significant reduction in cytokine levels and TBI biomarkers, particularly among patients with positive HsTnT, indicating a potential role in modulating inflammation post-TBI.
Practical Solutions and Value
This study provides valuable insights into the potential benefits of early beta-blocker administration in TBI patients, especially those with positive HsTnT levels.
The findings suggest a potential role for propranolol in modulating inflammation post-TBI and may guide future treatment strategies for TBI patients.
